STOCK TITAN

Qatar Investment Authority (BTAI) reports 156,066 BioXcel shares owned

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Qatar Investment Authority filed an amendment reporting beneficial ownership of 156,066 shares of BioXcel Therapeutics common stock. The filing states this equals 0.58% of the class based on 27,088,601 shares outstanding as of March 26, 2026. The filing attributes 142,051 shares to the wholly owned subsidiary Q Boost Holding LLC plus 14,015 shares issuable upon exercise of an issuer warrant; it explains a 1-for-16 reverse stock split effective February 7, 2025 and a cashless exercise on April 28, 2025.

Positive

  • None.

Negative

  • None.
Beneficially owned shares 156,066 shares Amount beneficially owned reported in Item 4
Percent of class 0.58% Percent of class reported in Item 4
Shares outstanding (calculation) 27,088,601 shares Used to calculate percent of class as of March 26, 2026
Shares held by subsidiary 142,051 shares Held by Q Boost Holding LLC after cashless exercise
Shares issuable on warrant 14,015 shares Shares issuable to subsidiary upon exercise of issuer warrant
Reverse stock split 1-for-16 Effective February 7, 2025
Cashless exercise date April 28, 2025 Cashless exercise by the subsidiary producing issued shares
beneficially owned regulatory
"Amount beneficially owned: 156,066.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
cashless exercise financial
"cashless exercise by the Subsidiary on April 28, 2025"
A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.
reverse stock split corporate
"1-for-16 reverse stock split of the Common Stock effective at 5:00 p.m."
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
warrant financial
"14,015 shares of Common Stock issuable to the Subsidiary upon exercise of the Issuer warrant"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.





09075P105

(CUSIP Number)
12/31/2025

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The numbers in rows 5, 7 and 9 represent 142,051 shares of Common Stock held by Q Boost Holding LLC, the Reporting Person's wholly owned subsidiary (the "Subsidiary"), and 14,015 shares of Common Stock issuable to the Subsidiary upon exercise of the Issuer warrant held by the Subsidiary. The percentage of class in row 11 is calculated assuming 27,088,601 shares of Common Stock are outstanding based on (i) 27,074,586 shares of Common Stock outstanding as of March 26, 2026 as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission on March 27, 2026 and (ii) 14,015 shares of Common Stock issuable to the Subsidiary upon exercise of the Issuer warrant held by the Subsidiary. The above numbers give effect to (i) a 1-for-16 reverse stock split of the Common Stock effective at 5:00 p.m. Eastern Time on February 7, 2025, and (ii) the cashless exercise by the Subsidiary on April 28, 2025 of an Issuer warrant to purchase 156,250 shares of Common Stock, resulting in the issuance of the 142,051 shares of Common Stock currently held by the Subsidiary after withholding 14,199 shares of Common Stock to satisfy the exercise price.


SCHEDULE 13G



Qatar Investment Authority
Signature:Mohammed Fahad Al Khulaifi
Name/Title:Head of Compliance and Governance
Date:03/30/2026

FAQ

What stake does Qatar Investment Authority hold in BioXcel (BTAI)?

QIA beneficially owns 156,066 shares, or 0.58% of BioXcel's class. This percentage uses 27,088,601 shares outstanding as of March 26, 2026, including 14,015 shares issuable upon exercise of a warrant.

How are the 156,066 shares held by Qatar Investment Authority structured?

142,051 shares are held by Q Boost Holding LLC and 14,015 are issuable on a warrant. The filing attributes holdings to the wholly owned subsidiary and details a prior cashless exercise that produced the subsidiary's current shares.

Did any corporate actions affect the reported share counts?

Yes — a 1-for-16 reverse stock split on February 7, 2025, and a cashless exercise of an issuer warrant on April 28, 2025, which resulted in withholding shares to cover the exercise price.

What outstanding share count was used to calculate the percent of class?

The percent is calculated using 27,088,601 shares outstanding as of March 26, 2026. That figure combines the Form 10-K's 27,074,586 shares and 14,015 shares issuable upon exercise of the subsidiary's warrant.
Bioxcel Therapeutics Inc

NASDAQ:BTAI

View BTAI Stock Overview

BTAI Rankings

BTAI Latest News

BTAI Latest SEC Filings

BTAI Stock Data

33.36M
23.57M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NEW HAVEN